BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rachiglio AM, Lambiase M, Fenizia F, Roma C, Cardone C, Iannaccone A, De Luca A, Carotenuto M, Frezzetti D, Martinelli E, Maiello E, Ciardiello F, Normanno N. Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. Cancers (Basel) 2019;11:E859. [PMID: 31226844 DOI: 10.3390/cancers11060859] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Liang L, Liu M, Sun X, Yuan Y, Peng K, Rashid K, Yu Y, Cui Y, Chen Y, Liu T. Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer. Cancer Cell Int 2021;21:135. [PMID: 33632198 DOI: 10.1186/s12935-021-01829-8] [Reference Citation Analysis]
2 Ramanathan S, Gopinath SCB, Arshad MKM, Poopalan P, Anbu P, Lakshmipriya T, Kasim FH. Aluminosilicate Nanocomposite on Genosensor: A Prospective Voltammetry Platform for Epidermal Growth Factor Receptor Mutant Analysis in Non-small Cell Lung Cancer. Sci Rep 2019;9:17013. [PMID: 31745155 DOI: 10.1038/s41598-019-53573-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
3 Feng Y, Hu T, Fang P, Zhou L, Li W, Fang Q, Fang J. Consecutive and automatic detection of multi-gene mutations from colorectal cancer samples by coupling droplet array-based capillary electrophoresis and PCR-RFLP. Anal Bioanal Chem 2020;412:3037-49. [PMID: 32249344 DOI: 10.1007/s00216-020-02567-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Giordano G, Remo A, Porras A, Pancione M. Immune Resistance and EGFR Antagonists in Colorectal Cancer. Cancers (Basel). 2019;11. [PMID: 31370270 DOI: 10.3390/cancers11081089] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
5 Martinelli E, Ciardiello D, Martini G, Troiani T, Cardone C, Vitiello PP, Normanno N, Rachiglio AM, Maiello E, Latiano T, De Vita F, Ciardiello F. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol 2020;31:30-40. [PMID: 31912793 DOI: 10.1016/j.annonc.2019.10.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 29.0] [Reference Citation Analysis]
6 Mendelaar PAJ, Smid M, van Riet J, Angus L, Labots M, Steeghs N, Hendriks MP, Cirkel GA, van Rooijen JM, Ten Tije AJ, Lolkema MP, Cuppen E, Sleijfer S, Martens JWM, Wilting SM. Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nat Commun 2021;12:574. [PMID: 33495476 DOI: 10.1038/s41467-020-20887-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Song K, Lu H, Jin L, Wang K, Guo W, Zheng H, Li K, He C, You T, Fu Y, Yang J, Zhao W, Guo Z. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer. FEBS J 2020;287:5236-48. [PMID: 32216031 DOI: 10.1111/febs.15306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Manzanares-Martin B, Cebrián Aranda A, Del Puerto-Nevado L, González R, Solanes S, Gómez-España MA, García-Foncillas J, Aranda E. Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes. J Immunother Cancer 2021;9:e001705. [PMID: 33833048 DOI: 10.1136/jitc-2020-001705] [Reference Citation Analysis]
9 Zhang H, Yuan L, Liu L, Yan C, Cheng J, Fu Q, Tong Z, Jiang W, Zheng Y, Zhao P, Zhang G, Fang W. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab. BMC Cancer 2020;20:416. [PMID: 32404198 DOI: 10.1186/s12885-020-06909-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shuford RA, Cairns AL, Moaven O. Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment. Cancers (Basel) 2020;12:E3481. [PMID: 33238500 DOI: 10.3390/cancers12113481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cheng KJ, Mejia Mohammed EH, Khong TL, Mohd Zain S, Thavagnanam S, Ibrahim ZA. IL-1α and colorectal cancer pathogenesis: Enthralling candidate for anti-cancer therapy. Crit Rev Oncol Hematol 2021;163:103398. [PMID: 34147647 DOI: 10.1016/j.critrevonc.2021.103398] [Reference Citation Analysis]
12 Rachiglio AM, Sacco A, Forgione L, Esposito C, Chicchinelli N, Normanno N. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. Exploration of Targeted Anti-tumor Therapy 2020;1:53-70. [DOI: 10.37349/etat.2020.00004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Mohd Yunos RI, Ab Mutalib NS, Tieng FYF, Abu N, Jamal R. Actionable Potentials of Less Frequently Mutated Genes in Colorectal Cancer and Their Roles in Precision Medicine. Biomolecules 2020;10:E476. [PMID: 32245111 DOI: 10.3390/biom10030476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]